Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis

Toll-like receptors (TLRs) have achieved an extraordinary amount of interest in cancer research due to their role in tumor progression. The aim of this study was to investigate the expression and clinical relevance of TLR3, 4, 7 and 9 in cutaneous malignant melanoma (CMM). The expression levels of T...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of Dermatological Research 2013, Vol.305 (1), p.59-67
Hauptverfasser: Eiró, N., Ovies, C., Fernandez-Garcia, B., Álvarez-Cuesta, C. C., González, L., González, L. O., Vizoso, F. J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 67
container_issue 1
container_start_page 59
container_title Archives of Dermatological Research
container_volume 305
creator Eiró, N.
Ovies, C.
Fernandez-Garcia, B.
Álvarez-Cuesta, C. C.
González, L.
González, L. O.
Vizoso, F. J.
description Toll-like receptors (TLRs) have achieved an extraordinary amount of interest in cancer research due to their role in tumor progression. The aim of this study was to investigate the expression and clinical relevance of TLR3, 4, 7 and 9 in cutaneous malignant melanoma (CMM). The expression levels of TLR3, 4, 7 and 9 were analyzed in tumors from 30 patients with CMM. The analysis was performed by immunohistochemistry, and the results were correlated with various clinicopathological findings and with relapse-free survival. Our results indicate that there was a wide variability in the immunostaining score values for each receptor. Positive staining for TLRs was generally found in tumor cells, especially for TLR4 and TLR9. Nevertheless, a significant percentage of tumors also showed TLR4 expression in mononuclear inflammatory cells (62.1 %) and in fibroblast-like cells (34.5 %). Our results showed no significant association between score values for each TLR and clinicopathological characteristics of patients. However, our results demonstrated that high TLR4 expression was significantly associated with a shortened relapse-free survival ( p  = 0.001). Therefore, TLR4 expression may be a new prognostic factor of unfavorable evolution in cutaneous malignant melanoma.
doi_str_mv 10.1007/s00403-012-1300-y
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1273156617</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2280628869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-942107df14a095675cf1a56c29541833c412294a678d4928ba259dde8fa7db1d3</originalsourceid><addsrcrecordid>eNp1kU1rFTEUhoMo9lL7A9xIwI2Ljp58TDJxJ6V-wAWhtOAu5GYy96bMJGOSQe-6f9zUqRYEs0kgz_uehAehlwTeEgD5LgNwYA0Q2hAG0ByfoA3hjDYg1LenaAOMQ8OEEifoLOdbqEsCpyCfoxPKiFRtxzfo7vLnnFzOPgYcB3y9vWLnmJ9jiU3oscI-YLsUE1xcMp7M6PfBhIInN5oQJ_Mep3oqNZ0PfsY_fDlgO_rgbZxNOcQx7r01I7YHk4wtLvlcvM2_y-cU9yFmn1-gZ4MZszt72E_RzcfL64vPzfbrpy8XH7aNZZKWRnFKQPYD4QZUK2RrB2JaYalqOekYs5xQqrgRsuu5ot3O0Fb1vesGI_sd6dkperP21snfF5eLnny2bhzX72lCJSOtEERW9PU_6G1cUqiv05R2IGjXCVUpslI2xZyTG_Sc_GTSURPQ95L0KklXSfpekj7WzKuH5mU3uf5v4o-SCtAVyPUq7F16HP3_1l_1vpya</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2280628869</pqid></control><display><type>article</type><title>Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Eiró, N. ; Ovies, C. ; Fernandez-Garcia, B. ; Álvarez-Cuesta, C. C. ; González, L. ; González, L. O. ; Vizoso, F. J.</creator><creatorcontrib>Eiró, N. ; Ovies, C. ; Fernandez-Garcia, B. ; Álvarez-Cuesta, C. C. ; González, L. ; González, L. O. ; Vizoso, F. J.</creatorcontrib><description>Toll-like receptors (TLRs) have achieved an extraordinary amount of interest in cancer research due to their role in tumor progression. The aim of this study was to investigate the expression and clinical relevance of TLR3, 4, 7 and 9 in cutaneous malignant melanoma (CMM). The expression levels of TLR3, 4, 7 and 9 were analyzed in tumors from 30 patients with CMM. The analysis was performed by immunohistochemistry, and the results were correlated with various clinicopathological findings and with relapse-free survival. Our results indicate that there was a wide variability in the immunostaining score values for each receptor. Positive staining for TLRs was generally found in tumor cells, especially for TLR4 and TLR9. Nevertheless, a significant percentage of tumors also showed TLR4 expression in mononuclear inflammatory cells (62.1 %) and in fibroblast-like cells (34.5 %). Our results showed no significant association between score values for each TLR and clinicopathological characteristics of patients. However, our results demonstrated that high TLR4 expression was significantly associated with a shortened relapse-free survival ( p  = 0.001). Therefore, TLR4 expression may be a new prognostic factor of unfavorable evolution in cutaneous malignant melanoma.</description><identifier>ISSN: 0340-3696</identifier><identifier>EISSN: 1432-069X</identifier><identifier>DOI: 10.1007/s00403-012-1300-y</identifier><identifier>PMID: 23179584</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - analysis ; Chi-Square Distribution ; Dermatology ; Disease-Free Survival ; Female ; Humans ; Immunohistochemistry ; Inflammation ; Kaplan-Meier Estimate ; Male ; Medical prognosis ; Medicine ; Medicine &amp; Public Health ; Melanoma ; Melanoma - immunology ; Melanoma - mortality ; Melanoma - pathology ; Melanoma - therapy ; Middle Aged ; Original Paper ; Skin cancer ; Skin Neoplasms - immunology ; Skin Neoplasms - mortality ; Skin Neoplasms - pathology ; Skin Neoplasms - therapy ; Time Factors ; TLR3 protein ; TLR4 protein ; TLR9 protein ; Toll-Like Receptor 3 - analysis ; Toll-Like Receptor 4 - analysis ; Toll-Like Receptor 7 - analysis ; Toll-Like Receptor 8 - analysis ; Toll-like receptors ; Treatment Outcome ; Tumor cells ; Tumors ; Up-Regulation ; Young Adult</subject><ispartof>Archives of Dermatological Research, 2013, Vol.305 (1), p.59-67</ispartof><rights>Springer-Verlag Berlin Heidelberg 2012</rights><rights>Archives of Dermatological Research is a copyright of Springer, (2012). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-942107df14a095675cf1a56c29541833c412294a678d4928ba259dde8fa7db1d3</citedby><cites>FETCH-LOGICAL-c372t-942107df14a095675cf1a56c29541833c412294a678d4928ba259dde8fa7db1d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00403-012-1300-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00403-012-1300-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23179584$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eiró, N.</creatorcontrib><creatorcontrib>Ovies, C.</creatorcontrib><creatorcontrib>Fernandez-Garcia, B.</creatorcontrib><creatorcontrib>Álvarez-Cuesta, C. C.</creatorcontrib><creatorcontrib>González, L.</creatorcontrib><creatorcontrib>González, L. O.</creatorcontrib><creatorcontrib>Vizoso, F. J.</creatorcontrib><title>Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis</title><title>Archives of Dermatological Research</title><addtitle>Arch Dermatol Res</addtitle><addtitle>Arch Dermatol Res</addtitle><description>Toll-like receptors (TLRs) have achieved an extraordinary amount of interest in cancer research due to their role in tumor progression. The aim of this study was to investigate the expression and clinical relevance of TLR3, 4, 7 and 9 in cutaneous malignant melanoma (CMM). The expression levels of TLR3, 4, 7 and 9 were analyzed in tumors from 30 patients with CMM. The analysis was performed by immunohistochemistry, and the results were correlated with various clinicopathological findings and with relapse-free survival. Our results indicate that there was a wide variability in the immunostaining score values for each receptor. Positive staining for TLRs was generally found in tumor cells, especially for TLR4 and TLR9. Nevertheless, a significant percentage of tumors also showed TLR4 expression in mononuclear inflammatory cells (62.1 %) and in fibroblast-like cells (34.5 %). Our results showed no significant association between score values for each TLR and clinicopathological characteristics of patients. However, our results demonstrated that high TLR4 expression was significantly associated with a shortened relapse-free survival ( p  = 0.001). Therefore, TLR4 expression may be a new prognostic factor of unfavorable evolution in cutaneous malignant melanoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Chi-Square Distribution</subject><subject>Dermatology</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Inflammation</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Melanoma</subject><subject>Melanoma - immunology</subject><subject>Melanoma - mortality</subject><subject>Melanoma - pathology</subject><subject>Melanoma - therapy</subject><subject>Middle Aged</subject><subject>Original Paper</subject><subject>Skin cancer</subject><subject>Skin Neoplasms - immunology</subject><subject>Skin Neoplasms - mortality</subject><subject>Skin Neoplasms - pathology</subject><subject>Skin Neoplasms - therapy</subject><subject>Time Factors</subject><subject>TLR3 protein</subject><subject>TLR4 protein</subject><subject>TLR9 protein</subject><subject>Toll-Like Receptor 3 - analysis</subject><subject>Toll-Like Receptor 4 - analysis</subject><subject>Toll-Like Receptor 7 - analysis</subject><subject>Toll-Like Receptor 8 - analysis</subject><subject>Toll-like receptors</subject><subject>Treatment Outcome</subject><subject>Tumor cells</subject><subject>Tumors</subject><subject>Up-Regulation</subject><subject>Young Adult</subject><issn>0340-3696</issn><issn>1432-069X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kU1rFTEUhoMo9lL7A9xIwI2Ljp58TDJxJ6V-wAWhtOAu5GYy96bMJGOSQe-6f9zUqRYEs0kgz_uehAehlwTeEgD5LgNwYA0Q2hAG0ByfoA3hjDYg1LenaAOMQ8OEEifoLOdbqEsCpyCfoxPKiFRtxzfo7vLnnFzOPgYcB3y9vWLnmJ9jiU3oscI-YLsUE1xcMp7M6PfBhIInN5oQJ_Mep3oqNZ0PfsY_fDlgO_rgbZxNOcQx7r01I7YHk4wtLvlcvM2_y-cU9yFmn1-gZ4MZszt72E_RzcfL64vPzfbrpy8XH7aNZZKWRnFKQPYD4QZUK2RrB2JaYalqOekYs5xQqrgRsuu5ot3O0Fb1vesGI_sd6dkperP21snfF5eLnny2bhzX72lCJSOtEERW9PU_6G1cUqiv05R2IGjXCVUpslI2xZyTG_Sc_GTSURPQ95L0KklXSfpekj7WzKuH5mU3uf5v4o-SCtAVyPUq7F16HP3_1l_1vpya</recordid><startdate>2013</startdate><enddate>2013</enddate><creator>Eiró, N.</creator><creator>Ovies, C.</creator><creator>Fernandez-Garcia, B.</creator><creator>Álvarez-Cuesta, C. C.</creator><creator>González, L.</creator><creator>González, L. O.</creator><creator>Vizoso, F. J.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>2013</creationdate><title>Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis</title><author>Eiró, N. ; Ovies, C. ; Fernandez-Garcia, B. ; Álvarez-Cuesta, C. C. ; González, L. ; González, L. O. ; Vizoso, F. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-942107df14a095675cf1a56c29541833c412294a678d4928ba259dde8fa7db1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Chi-Square Distribution</topic><topic>Dermatology</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Inflammation</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Melanoma</topic><topic>Melanoma - immunology</topic><topic>Melanoma - mortality</topic><topic>Melanoma - pathology</topic><topic>Melanoma - therapy</topic><topic>Middle Aged</topic><topic>Original Paper</topic><topic>Skin cancer</topic><topic>Skin Neoplasms - immunology</topic><topic>Skin Neoplasms - mortality</topic><topic>Skin Neoplasms - pathology</topic><topic>Skin Neoplasms - therapy</topic><topic>Time Factors</topic><topic>TLR3 protein</topic><topic>TLR4 protein</topic><topic>TLR9 protein</topic><topic>Toll-Like Receptor 3 - analysis</topic><topic>Toll-Like Receptor 4 - analysis</topic><topic>Toll-Like Receptor 7 - analysis</topic><topic>Toll-Like Receptor 8 - analysis</topic><topic>Toll-like receptors</topic><topic>Treatment Outcome</topic><topic>Tumor cells</topic><topic>Tumors</topic><topic>Up-Regulation</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eiró, N.</creatorcontrib><creatorcontrib>Ovies, C.</creatorcontrib><creatorcontrib>Fernandez-Garcia, B.</creatorcontrib><creatorcontrib>Álvarez-Cuesta, C. C.</creatorcontrib><creatorcontrib>González, L.</creatorcontrib><creatorcontrib>González, L. O.</creatorcontrib><creatorcontrib>Vizoso, F. J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of Dermatological Research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eiró, N.</au><au>Ovies, C.</au><au>Fernandez-Garcia, B.</au><au>Álvarez-Cuesta, C. C.</au><au>González, L.</au><au>González, L. O.</au><au>Vizoso, F. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis</atitle><jtitle>Archives of Dermatological Research</jtitle><stitle>Arch Dermatol Res</stitle><addtitle>Arch Dermatol Res</addtitle><date>2013</date><risdate>2013</risdate><volume>305</volume><issue>1</issue><spage>59</spage><epage>67</epage><pages>59-67</pages><issn>0340-3696</issn><eissn>1432-069X</eissn><abstract>Toll-like receptors (TLRs) have achieved an extraordinary amount of interest in cancer research due to their role in tumor progression. The aim of this study was to investigate the expression and clinical relevance of TLR3, 4, 7 and 9 in cutaneous malignant melanoma (CMM). The expression levels of TLR3, 4, 7 and 9 were analyzed in tumors from 30 patients with CMM. The analysis was performed by immunohistochemistry, and the results were correlated with various clinicopathological findings and with relapse-free survival. Our results indicate that there was a wide variability in the immunostaining score values for each receptor. Positive staining for TLRs was generally found in tumor cells, especially for TLR4 and TLR9. Nevertheless, a significant percentage of tumors also showed TLR4 expression in mononuclear inflammatory cells (62.1 %) and in fibroblast-like cells (34.5 %). Our results showed no significant association between score values for each TLR and clinicopathological characteristics of patients. However, our results demonstrated that high TLR4 expression was significantly associated with a shortened relapse-free survival ( p  = 0.001). Therefore, TLR4 expression may be a new prognostic factor of unfavorable evolution in cutaneous malignant melanoma.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>23179584</pmid><doi>10.1007/s00403-012-1300-y</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0340-3696
ispartof Archives of Dermatological Research, 2013, Vol.305 (1), p.59-67
issn 0340-3696
1432-069X
language eng
recordid cdi_proquest_miscellaneous_1273156617
source MEDLINE; SpringerLink Journals
subjects Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - analysis
Chi-Square Distribution
Dermatology
Disease-Free Survival
Female
Humans
Immunohistochemistry
Inflammation
Kaplan-Meier Estimate
Male
Medical prognosis
Medicine
Medicine & Public Health
Melanoma
Melanoma - immunology
Melanoma - mortality
Melanoma - pathology
Melanoma - therapy
Middle Aged
Original Paper
Skin cancer
Skin Neoplasms - immunology
Skin Neoplasms - mortality
Skin Neoplasms - pathology
Skin Neoplasms - therapy
Time Factors
TLR3 protein
TLR4 protein
TLR9 protein
Toll-Like Receptor 3 - analysis
Toll-Like Receptor 4 - analysis
Toll-Like Receptor 7 - analysis
Toll-Like Receptor 8 - analysis
Toll-like receptors
Treatment Outcome
Tumor cells
Tumors
Up-Regulation
Young Adult
title Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T03%3A02%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20TLR3,%204,%207%20and%209%20in%20cutaneous%20malignant%20melanoma:%20relationship%20with%20clinicopathological%20characteristics%20and%20prognosis&rft.jtitle=Archives%20of%20Dermatological%20Research&rft.au=Eir%C3%B3,%20N.&rft.date=2013&rft.volume=305&rft.issue=1&rft.spage=59&rft.epage=67&rft.pages=59-67&rft.issn=0340-3696&rft.eissn=1432-069X&rft_id=info:doi/10.1007/s00403-012-1300-y&rft_dat=%3Cproquest_cross%3E2280628869%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2280628869&rft_id=info:pmid/23179584&rfr_iscdi=true